Articles

A study looking at the ways in which different countries handle appraisal and reimbursement processes for rare disease treatments (RDTs) revealed that implementing supplemental processes can aid in patient and physician decision making.

Supplemental Process Can Aid in Assessing Value of Rare Disease Treatments

Videos

In addressing the COVID-19 pandemic, a more active-based approach is warranted among employers to optimize care. Through detailed databases and a greater focus on population health, Paladina Health has promoted this transition to a more informed, value-based health care delivery system, said Kirk Rosin, chief revenue officer of Paladina Health.

How Can Integrating Data, Population Health Optimize Employer Health Care Delivery Amid COVID-19?

Expanding Treatment Options for Metastatic Breast Cancer

Technology has made it easier to deliver health care in the home in recent years, but the financing models have not caught up just yet.

Is Home Care Going Mainstream in the United States?

The American Society of Hematology has adopted 10 of the recommendations from Choosing Wisely to encourage more high-value care, but barriers to adoption remain.

What Are the Barriers to Choosing Wisely in Hematology Care?

Administrator Seema Verma said the proposal would create opportunities "for drug manufacturers to have skin in the game through payment arrangements that challenge them to put their money where their mouth is."

CMS Issues Rules to Promote Value-Based Contracting, Pay for High-Cost Therapies in Medicaid

Could the COVID-19 Pandemic Create New Opportunities for the Adoption of APMs and Be a Catalyst for the Movement From Volume to Value?

Unlike in fee-for-service, we have an amazing opportunity to begin to understand and build in factors that will keep patients healthy and give them the best outcomes possible, said Lili Brillstein, CEO of Brillstein Collaborative Consulting, and former Director for Episodes of Care at Horizon Blue Cross Blue Shield of New Jersey.

Lili Brillstein Discusses Incorporating Social Determinants of Health Into Value-Based Care

There will never be all mandatory payment models or all value-based models, but we can craft a value-based model around just about anything as long as everybody agrees on what the criteria is, said Lili Brillstein, CEO of Brillstein Collaborative Consulting, and former Director for Episodes of Care at Horizon Blue Cross Blue Shield of New Jersey.

Lili Brillstein on Mandatory, Voluntary Payment Models

When deciding which treatments to cover, states and commercial payers must wrestle with opportunity costs as new therapeutics come to market. A panel at Virtual ISPOR 2020 discussed some of the factors that go into those decisions.

IVBM